Latest news with #DyneTherapeutics
Business Insider
12-07-2025
- Business
- Business Insider
Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner lowered the firm's price target on Dyne Therapeutics (DYN) to $41 from $46 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a 'notable lengthening' of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
11-07-2025
- Business
- Yahoo
RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT
Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7, Luca Issi from RBC Capital maintained a Buy rating on Dyne Therapeutics, Inc. (NASDAQ:DYN) with a price target of $25.00. A lab technician working with chemicals and equipment to create a novel therapeutic drug. In other news, Dyne Therapeutics, Inc. (NASDAQ:DYN) announced on June 30 that it entered into a $275 million non-dilutive senior secured term loan facility with Hercules Capital. The company expects the transaction to bolster its balance sheet as it continues with DYNE-101 and DYNE-251 through critical clinical and regulatory milestones, for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), respectively. John Cox, president and chief executive officer of Dyne, stated that the company is well-positioned to execute its plans to deliver functional improvement to the neuromuscular community, supported by '$100 million funded upfront and access to additional capital aligned with clinical, regulatory, and commercial progress.' Dyne Therapeutics, Inc. (NASDAQ:DYN) is also nearing a potential US launch in DMD in 2027. Dyne Therapeutics, Inc. (NASDAQ:DYN) develops innovative life-transforming therapies for genetically driven muscle diseases. The company has a brand portfolio for muscle diseases, including facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1, and Duchenne muscular dystrophy. While we acknowledge the potential of DYN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
11-07-2025
- Business
- Yahoo
RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT
Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7, Luca Issi from RBC Capital maintained a Buy rating on Dyne Therapeutics, Inc. (NASDAQ:DYN) with a price target of $25.00. A lab technician working with chemicals and equipment to create a novel therapeutic drug. In other news, Dyne Therapeutics, Inc. (NASDAQ:DYN) announced on June 30 that it entered into a $275 million non-dilutive senior secured term loan facility with Hercules Capital. The company expects the transaction to bolster its balance sheet as it continues with DYNE-101 and DYNE-251 through critical clinical and regulatory milestones, for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), respectively. John Cox, president and chief executive officer of Dyne, stated that the company is well-positioned to execute its plans to deliver functional improvement to the neuromuscular community, supported by '$100 million funded upfront and access to additional capital aligned with clinical, regulatory, and commercial progress.' Dyne Therapeutics, Inc. (NASDAQ:DYN) is also nearing a potential US launch in DMD in 2027. Dyne Therapeutics, Inc. (NASDAQ:DYN) develops innovative life-transforming therapies for genetically driven muscle diseases. The company has a brand portfolio for muscle diseases, including facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1, and Duchenne muscular dystrophy. While we acknowledge the potential of DYN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-07-2025
- Business
- Yahoo
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 3,636,363 shares of its common stock at the public offering price, less the underwriting discounts and commissions. Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering. Jones is acting as co-manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission ('SEC') on March 5, 2024 and became automatically effective upon filing. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC's website at A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@ Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@ Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@ or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the anticipated closing date of the public offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'objective,' 'ongoing,' 'plan,' 'predict,' 'project,' 'potential,' 'should,' or 'would,' or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the risks and uncertainties related to the satisfaction of customary closing conditions for the public offering and other factors discussed in the 'Risk Factors' section of the preliminary prospectus supplement filed with the SEC on June 30, 2025, as well as the risks and uncertainties identified in Dyne's filings with the SEC, including Dyne's most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release. Contacts: Investors Mia Tobiasir@ Media Stacy Nartkersnartker@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-06-2025
- Business
- Yahoo
Dyne at ‘attractive entry point' following pullback, says Chardan
Chardan notes Dyne Therapeutics (DYN) announced updates for its DYNE-101 program for myotonic dystrophy type 1, which included an update on regulatory alignment with the FDA regarding an accelerated approval pathway and updated data, out to 12-months, for the 6.8 mg/kg dose from the ACHIEVE trial. An accelerated approval pathway for DYNE-101 targeting DM1 requires the company to revise the protocol for the registrational expansion cohort of the ACHIEVE trial, switching to video hand opening time as the primary endpoint, notes the analyst, who believes that the confirmation by the FDA of an accelerated approval pathway 'more than offsets' what could be a six month delay from prior estimates of a BLA submission. The firm, which maintains its Buy rating and 12-month price target of $50 on Dyne shares, argues that with the stock having declined 41% year-to-date at yesterday's close that the current stock price 'represents an attractive entry point.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on DYN: Disclaimer & DisclosureReport an Issue Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly Dyne Therapeutics: Strategic Shift to vHOT and FDA Support Bolster Buy Rating Dyne Therapeutics pivot on primary endpoint will 'raise questions,' says Stifel Dyne Therapeutics sinks 20% after changing study endpoint Dyne Therapeutics Granted Breakthrough Therapy Designation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
